---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023492"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:53:02.934155+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR

## Summary
- Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.
- Cash totaled $1.7M as of Sept 30, 2025; completed convertible preferred stock offering in Nov 2025 for $4M gross, with up to $16M additional over 24 months.
- Initiated pivotal Phase 3 trial (PF614-301) for PF614 in moderate to severe post-surgical pain in July 2025.
- FDA supported PF614-MPAR development for overdose protection labeling and confirmed potential streamlined 505(b)(2) pathway.
- R&D expenses increased to $3.0M from $1.7M YoY; grant revenue fell to $0.5M from $3.4M.

## SEC filing metadata
- accession: 0001493152-25-023492
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/0001493152-25-023492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023492
- JSON: https://secwatch.observer/filing/0001493152-25-023492.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023492.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.